CR:DOI:2483a49cfbd2a70760de3abb1cb8a780
From IDWiki
{{#scite:
|reference=maertens2016is
|type=journal-article
|title=Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
|author=Johan A Maertens;Issam I Raad;Kieren A Marr;Thomas F Patterson;Dimitrios P Kontoyiannis;Oliver A Cornely;Eric J Bow;Galia Rahav;Dionysios Neofytos;Mickael Aoun;John W Baddley;Michael Giladi;Werner J Heinz;Raoul Herbrecht;William Hope;Meinolf Karthaus;Dong-Gun Lee;Olivier Lortholary;Vicki A Morrison;Ilana Oren;Dominik Selleslag;Shmuel Shoham;George R Thompson;Misun Lee;Rochelle M Maher;Anne-Hortense Schmitt-Hoffmann;Bernhardt Zeiher;Andrew J Ullmann|+sep=;
|journal=The Lancet
|publisher=Elsevier BV
|year=2016
|volume=387
|issue=10020
|pages=760-769
|doi=10.1016/s0140-6736(15)01159-9
|issn=0140-6736
|retrieved-from=https://dx.doi.org/
|retrieved-on=2024-10-01
}}
